›› 2010, Vol. 30 ›› Issue (3): 336-.

• Original article (Clinical research) • Previous Articles     Next Articles

Changes of plasma NT-ProBNP and MMP-2 levels and relationship with left ventricular remodeling in patients treated by pravastatin with CHF after PCI therapy for AMI

HUANG Yu1, LEI Hai-fang2, WEI Meng3, QIU Jian-ping1, QIU Geng4, LU Ji-de1   

  1. 1. Department of Cardiology, Gongli Hospital of Pudong New Area, Shanghai 200135, China；2. Ningxia Medical University, Yinchuan 750004, China；3. Department of Cardiology, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200223, China；4. Shanghai Da An Center for Medical Laboratory, Shanghai 201203, China
  • Online:2010-03-25 Published:2010-03-24
  • Supported by:

    Shanghai Science and Technology Committee Foundation, 034119853；Foundation of Social Development Bureau of Pudong New Area, PW2009D-2

PDF (PC)

1392

Abstract:

Objective To observe the effects of pravastatin on plasma N-terminal pro-brain natriuretic peptide (NT-ProBNP), matrix metalloproteinase-2 (MMP-2) and left ventricular remodeling in patients with stable chronic heart failure (CHF）after percutaneous coronary intervention (PCI) therapy for acute myocardial infarction (AMI), and explore their relationship. Methods Ninety-six patients with CHF (Ⅱ/Ⅲ of NYHA Classification) after PCI therapy for AMI were randomly divided into pravastatin 20 mg group (treated by 20 mg pravastatin, n=52) and pravastatin 40 mg group (treated by 40 mg pravastatin, n=44). The general conditions before treatment by pravastatin, the changes of plasma NT-ProBNP and MMP-2 levels and parameters of left ventricular remodeling before treatment and 18 months after treatment by pravastatin were compared between two groups, and their relationship was explored. Results The plasma levels of NT-proBNP and MMP-2 after treatment were significantly lower than those before treatment in both groups (P<0.05), and the plasma levels of NT-proBNP and MMP-2 after treatment in pravastatin 40 mg group were significantly lower than those in pravastatin 20 mg group (P<0.05). After treatment by pravastatin, left ventricular mass index (LVMI), left ventricular end-diastolic dimension (LVEDD) and end-diastolic left ventricular posterior wall thickness (LVPWT) in both groups were significantly lower than those before treatment (P<0.01), and these parameters in pravastatin 40 mg group were significantly lower than those in pravastatin 20 mg group (P<0.01). After treatment by pravastatin, enddiastolic interventricular septal thickness (IVST), left ventricular shortening fraction (FS), mean velocity of circumferential fiber shortening of left ventricle (MVCF) and E/A in both groups were significantly higher than those before treatment (P<0.01), and these parameters in pravastatin 40 mg group were significantly higher than those in pravastatin 20 mg group (P<0.01). The decrease of plasma NT-proBNP and MMP-2 after treatment in both groups was positively related to the decrease of LVMI, LVEDD and LVPWT, and was negatively related to the increase of IVST, FS, MVCF and E/A (P<0.05). The decrease of plasma NT-proBNP was positively related to the decrease of MMP-2 (P<0.05). Conclusion Provastatin has beneficial effects on cardiac function of stable CHF after PCI therapy for AMI, which may be related to the inhibition of MMP-2 and left ventricular remodeling.

Key words: pravastatin, acute myocardial infarction, chronic heart failure, N-terminal pro-brain natriuretic peptide, left ventricular remodeling, matrix metalloproteinase-2